Immunohistochemical Profile and Prognostic Significance in Primary Central Nervous System Lymphoma: Analysis of 89 Cases
Overview
Authors
Affiliations
The majority of primary central nervous system lymphomas (PCNSLs) are diffuse large B cell lymphoma, characterized by poor prognosis. In the present study, the expression of cluster of differentiation (CD)10, B cell lymphoma (BCL)-6, multiple myeloma-1 (MUM-1), BCL-2, CD138 and Ki-67 was analyzed by immunohistochemistry in 89 Chinese PCNSL cases, and the potential prognostic significance was evaluated. CD10, BCL-6, MUM-1, BCL-2 and CD138 were positive in 16.9 (15/89), 51.7 (46/89), 92.1 (82/89), 73.3 (63/86) and 0% (0/65) of all cases, respectively. According to the Hans algorithm, 71 patients (79.8%) were classified into the non-germinal center B cell-like (non-GCB) group, indicating a post-germinal center origin of PCNSL. The median follow-up time of 73 patients was 13 months [95% confidence interval (CI), 10.93-15.08]. The median overall survival (OS) time was 45.3 months (95% CI, 25.01-65.59) and the median progression-free survival (PFS) time was 30.0 months (95% CI, 13.43-46.57). Age (>60 years) was associated with a shorter OS time (P=0.009). Ki-67 (cutoff point 90%) was associated with shorter OS (P=0.037) and shorter PFS (P=0.039) times. No other immunohistochemical markers were associated with prognosis. On multivariate analysis, age (>60 years) was associated with shorter OS time (P=0.038), but immunophenotype and expression status of Ki-67, CD10, BCL-6 and BCL-2 did not predict prognosis. In conclusion, high Ki-67 expression may predict poor prognosis in PCNSL. The present study was limited by its sample size and short follow-up time. This requires more evidence to further clinical study.
Yang C, Ren X, Cui Y, Jiang H, Li M, Yu K Front Immunol. 2025; 16:1438001.
PMID: 40040699 PMC: 11876112. DOI: 10.3389/fimmu.2025.1438001.
Shen Y, Wu S, Wu Y, Cui C, Li H, Yang S BMC Med Imaging. 2025; 25(1):54.
PMID: 39962371 PMC: 11834475. DOI: 10.1186/s12880-025-01585-5.
Zhao E, Yang Y, Bai M, Zhang H, Yang Y, Song X Front Med (Lausanne). 2024; 11:1345162.
PMID: 38994341 PMC: 11236568. DOI: 10.3389/fmed.2024.1345162.
Updates of primary central nervous system lymphoma.
Wu J, Zhou D, Zhu X, Zhang Y, Xiao Y Ther Adv Hematol. 2024; 15:20406207241259010.
PMID: 38883164 PMC: 11177745. DOI: 10.1177/20406207241259010.
Extranodal lymphoma: pathogenesis, diagnosis and treatment.
Yang H, Xun Y, Ke C, Tateishi K, You H Mol Biomed. 2023; 4(1):29.
PMID: 37718386 PMC: 10505605. DOI: 10.1186/s43556-023-00141-3.